Utilizing sparsentan may reduce the risk of death and kidney failure in FSGS patients.

Published Date: 05 Nov 2023

The DUPLEX trial failed to reach its primary endpoint of eGFR slope in FSGS patients; however, results indicate that sparsentan use reduces proteinuria and kidney failure risk more than irbesartan use does, thus supporting sparsentan as a standard treatment for glomerular disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Common intracellular toxin could help fight leukemia

2.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

3.

Scholastic performance is a key concern for young cancer patients, study finds

4.

AACR: American Association for Cancer Research

5.

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot